← Leaderboards
Georgia D Tomaras
Fred Hutchinson Cancer Center
$127,423,185
Attributed
$429,563,792
Total exposure
22
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $155.4M · FY2005–25$200M$150M$100M$50M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$483,817,974 · 25
By mechanism
UM1$400,541,390 · 1
P01$59,051,353 · 13
P30$16,933,778 · 5
T32$3,320,409 · 2
R01$2,183,396 · 2
R13$1,400,000 · 1
Top collaborators
- Dan H. Barouch19 shared
- Lawrence Corey19 shared
- Glenda E Gray19 shared
- Nathan M Thielman9 shared
- Susanna Naggie3 shared
- Guido Ferrari1 shared
- Allan D. Kirk1 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Peter B. Gilbert$223,972,501
- Yunda Huang$75,372,842
- Holly Janes$70,932,400
- Margaret Juliana McElrath$601,692,649
- Lawrence Corey$859,232,520
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesMediatingVaccinesProgramsInfectionHiv-1CellsVirusPhenotypeCollaborationsBaseFc ReceptorImmuneNonhuman PrimateMonoclonal AntibodiesVaccine TrialVaccine DesignHiv VaccineNeutralizing AntibodyResponseLeadershipLeadResearch PersonnelEpitopes
Grant awards (101)
HIV Vaccines Clinical Trials Network Leadership and Operations Center$30,396,659
UM1 · FY2025 · AI
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ$4,846,751
P01 · FY2025 · AI · contact PI
Center for AIDS Research$2,883,369
P30 · FY2025 · AI · contact PI
Antiviral Activity In Situ$1,057,042
P01 · FY2025 · AI · contact PI
Structure-Function Analytics Core$765,296
P01 · FY2025 · AI · contact PI
Administrative Core$650,889
P30 · FY2025 · AI · contact PI
Administrative Core$523,989
P01 · FY2025 · AI · contact PI
Mechanisms of Antibody Fc Mediated Protection$400,000
P01 · FY2025 · AI · contact PI
Advanced Immunobiology Traning Program for Surgeons$281,722
T32 · FY2025 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$21,949,062
UM1 · FY2024 · AI
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ$4,307,324
P01 · FY2024 · AI · contact PI
LOC: HIV Vaccine Trials Network$2,797,660
UM1 · FY2024 · AI
Centers for AIDS Research (CFAR)$2,250,000
P30 · FY2024 · AI · contact PI
Antiviral Activity In Situ$1,070,231
P01 · FY2024 · AI · contact PI
Structure-Function Analytics Core$734,396
P01 · FY2024 · AI · contact PI
Mechanisms of Antibody Fc Mediated Protection$618,001
P01 · FY2024 · AI · contact PI
Centers for AIDS Research (CFAR)$472,365
P30 · FY2024 · AI · contact PI
Administrative Core$279,298
P01 · FY2024 · AI · contact PI
Immunology Core (Basic Science Core)$138,597
P30 · FY2024 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$38,851,667
UM1 · FY2023 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$19,404,520
UM1 · FY2023 · AI
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ$4,448,363
P01 · FY2023 · AI · contact PI
Centers for AIDS Research (CFAR)$2,798,920
P30 · FY2023 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$2,683,830
UM1 · FY2023 · AI
Structure-Function Analytics Core$1,009,211
P01 · FY2023 · AI · contact PI
Mechanisms of Antibody Fc Mediated Protection$856,265
P01 · FY2023 · AI · contact PI
Antiviral Activity In Situ$591,426
P01 · FY2023 · AI · contact PI
Evaluating the use of long-acting antiretroviral treatment for HIV during community re-entry: Addressing community and structural barriers$506,691
P30 · FY2023 · AI · contact PI
CoVPN 3001$305,278
UM1 · FY2023 · AI
Administrative Core$259,009
P01 · FY2023 · AI · contact PI
Immunology Core (Basic Science Core)$151,490
P30 · FY2023 · AI · contact PI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$55,953,346
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$34,194,667
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$17,943,267
UM1 · FY2022 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$9,754,127
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$6,272,147
UM1 · FY2022 · AI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC$5,663,427
UM1 · FY2022 · AI
CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16$5,323,993
UM1 · FY2022 · AI
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ$4,260,726
P01 · FY2022 · AI · contact PI
CoVPN 3001 GY16 PostMerger LOC$3,879,990
UM1 · FY2022 · AI
Centers for AIDS Research (CFAR)$2,688,655
P30 · FY2022 · AI · contact PI
Antiviral Activity In Situ$852,788
P01 · FY2022 · AI · contact PI
Structure-Function Analytics Core$734,396
P01 · FY2022 · AI · contact PI
Mechanisms of Antibody Fc Mediated Protection$591,426
P01 · FY2022 · AI · contact PI
Administrative Core$301,978
P01 · FY2022 · AI · contact PI
CoVPN 3502 A Phase 3, Randomized, Double LOC GY16$293,963
UM1 · FY2022 · AI
Immunology Core (Basic Science Core)$157,663
P30 · FY2022 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$61,429,109
UM1 · FY2021 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$43,124,622
UM1 · FY2021 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$40,320,056
UM1 · FY2021 · AI
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ$4,343,297
P01 · FY2021 · AI · contact PI
Centers for AIDS Research (CFAR)$3,301,919
P30 · FY2021 · AI · contact PI
Antiviral Activity In Situ$1,000,205
P01 · FY2021 · AI · contact PI
Structure-Function Analytics Core$764,896
P01 · FY2021 · AI · contact PI
Mechanisms of Antibody Fc Mediated Protection$606,676
P01 · FY2021 · AI · contact PI
Administrative Core$332,063
P01 · FY2021 · AI · contact PI
Immunology Core (Basic Science Core)$131,940
P30 · FY2021 · AI · contact PI
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates$4,104,799
P01 · FY2020 · AI · contact PI
Antigen-specific NK cell memory$1,062,410
P01 · FY2020 · AI · contact PI
HIV-1 Env Immune Complexes and FcR-dependent Immunity$587,915
P01 · FY2020 · AI · contact PI
Interdisciplinary Research Training Program in AIDS$446,162
T32 · FY2020 · AI
Administrative Core$197,120
P01 · FY2020 · AI · contact PI
Immunology Core (Basic Science Core)$150,494
P30 · FY2020 · AI · contact PI
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates$3,342,424
P01 · FY2019 · AI · contact PI
HIV-1 Env Immune Complexes and FcR-dependent Immunity$500,493
P01 · FY2019 · AI · contact PI
Antigen-specific NK cell memory$493,801
P01 · FY2019 · AI · contact PI
Ruth L. Kirschstein National Research Service Award (NRSA)- T32$417,562
T32 · FY2019 · AI
Administrative Core$181,115
P01 · FY2019 · AI · contact PI
Immunology Core$102,807
P30 · FY2019 · AI · contact PI
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates$3,192,636
P01 · FY2018 · AI · contact PI
HIV Research for Prevention 2018: Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P)$1,400,000
R13 · FY2018 · AI · contact PI
HIV-1 Env Immune Complexes and FcR-dependent Immunity$495,270
P01 · FY2018 · AI · contact PI
Ruth L. Kirschstein National Research Service Award (NRSA)- T32$411,509
T32 · FY2018 · AI
Antigen-specific NK cell memory$343,251
P01 · FY2018 · AI · contact PI
Administrative Core$228,642
P01 · FY2018 · AI · contact PI
Immunology Core$130,167
P30 · FY2018 · AI · contact PI
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates$3,241,864
P01 · FY2017 · AI · contact PI
HIV-1 Env Immune Complexes and FcR-dependent Immunity$500,500
P01 · FY2017 · AI · contact PI
Antigen-specific NK cell memory$348,003
P01 · FY2017 · AI · contact PI
Ruth L. Kirschstein National Research Service Award (NRSA)- T32$293,890
T32 · FY2017 · AI
Administrative Core$183,551
P01 · FY2017 · AI · contact PI
Immunology Core$114,049
P30 · FY2017 · AI · contact PI
Ruth L. Kirschstein National Research Service Award (NRSA)- T32$8,644
T32 · FY2017 · AI
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates$3,264,079
P01 · FY2016 · AI · contact PI
HIV-1 Env Immune Complexes and FcR-dependent Immunity$637,797
P01 · FY2016 · AI · contact PI
Antigen-specific NK cell memory$443,467
P01 · FY2016 · AI · contact PI
Ruth L. Kirschstein National Research Service Award (NRSA)- T32$367,915
T32 · FY2016 · AI
Administrative Core$147,163
P01 · FY2016 · AI · contact PI
Immunology Core$144,561
P30 · FY2016 · AI · contact PI
Ruth L. Kirschstein National Research Service Award (NRSA)- T32$422,664
T32 · FY2015 · AI
Immunology Core$159,202
P30 · FY2015 · AI · contact PI
Interdisciplinary Research Training Program in AIDS$300,216
T32 · FY2014 · AI
Interdisciplinary Research Training Program in AIDS$370,125
T32 · FY2013 · AI
HIV-1 Gene Suppression by CD8+ T Cells$387,648
R56 · FY2012 · AI · contact PI
HIV-1 Gene Suppression by CD8+ T Cells$308,880
R01 · FY2010 · AI · contact PI
HIV-1 Gene Suppression by CD8+ T Cells$312,000
R01 · FY2009 · AI · contact PI
HIV-1 Gene Suppression by CD8+ T Cells$358,080
R01 · FY2008 · AI · contact PI
HIV-1 Gene Suppression by CD8+T Cell$308,000
R01 · FY2005 · AI
HIV-1 Gene Suppression by CD8+T Cell$308,000
R01 · FY2004 · AI
HIV-1 Gene Suppression by CD8+T Cell$308,000
R01 · FY2003 · AI
CD8+ CELL NONCYTOLYTIC INHIBITION OF HIV-1$280,436
R01 · FY2000 · AI